Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothe...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Onco Targets Ther
Hoofdauteurs: Peng, Yanmei, Cui, Huijuan, Liu, Zhe, Liu, Daiwei, Liu, Fan, Song, Yazhong, Duan, Hua, Qiu, Yuqin, Li, Qiang
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2017
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414636/
https://ncbi.nlm.nih.gov/pubmed/28490886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S130990
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items